Advertisement

Novel Insights into Anti-inflammatory Therapy in Sepsis-Induced ARDS

  • Jiaxiang Zhang
  • Ruilan Wang
Chapter

Abstract

Acute respiratory distress syndrome (ARDS) is a life-threatening complication caused by diverse conditions such as sepsis, trauma, and so on. Despite recent advances in understanding and management of ARDS, the mortality rate of ARDS remains high. Given the complex dysregulated inflammatory cascade in ARDS, there is an increasing interest in anti-inflammatory therapy targeted at improving the outcome of ARDS. This review will summarize current and future direction of anti-inflammatory therapy in ARDS.

Keywords

Acute respiratory distress syndrome Sepsis Anti-inflammatory therapy 

References

  1. 1.
    Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685–93.CrossRefGoogle Scholar
  2. 2.
    Hudson LD, Steinberg KP. Epidemiology of acute lung injury and ARDS. Chest. 1999;116(1 Suppl):74s–82s.CrossRefGoogle Scholar
  3. 3.
    Stapleton RD, Wang BM, Hudson LD, Rubenfeld GD, Caldwell ES, Steinberg KP. Causes and timing of death in patients with ARDS. Chest. 2005;128(2):525–32.CrossRefGoogle Scholar
  4. 4.
    Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–51.CrossRefGoogle Scholar
  5. 5.
    Vestweber D, Winderlich M, Cagna G, Nottebaum AF. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol. 2009;19(1):8–15.CrossRefGoogle Scholar
  6. 6.
    Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest. 2012;122(8):2731–40.CrossRefGoogle Scholar
  7. 7.
    Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest. 1987;92(6):1032–6.CrossRefGoogle Scholar
  8. 8.
    Weigelt JA, Norcross JF, Borman KR, Snyder WH 3rd. Early steroid therapy for respiratory failure. Arch Surg. 1985;120(5):536–40.CrossRefGoogle Scholar
  9. 9.
    Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;138(1):62–8.CrossRefGoogle Scholar
  10. 10.
    Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317(25):1565–70.CrossRefGoogle Scholar
  11. 11.
    Keel JB, Hauser M, Stocker R, Baumann PC, Speich R. Established acute respiratory distress syndrome: benefit of corticosteroid rescue therapy. Respiration. 1998;65(4):258–64.CrossRefGoogle Scholar
  12. 12.
    Meduri GU, Belenchia JM, Estes RJ, Wunderink RG, el Torky M, Leeper KV Jr. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest. 1991;100(4):943–52.CrossRefGoogle Scholar
  13. 13.
    Biffl WL, Moore FA, Moore EE, Haenel JB, McIntyre RC Jr, Burch JM. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am J Surg. 1995;170(6):591–5; discussion 595–596.CrossRefGoogle Scholar
  14. 14.
    Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159–65.CrossRefGoogle Scholar
  15. 15.
    Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med. 2002;165(7):983–91.CrossRefGoogle Scholar
  16. 16.
    Annane D, Sebille V, Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 2006;34(1):22–30.CrossRefGoogle Scholar
  17. 17.
    Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954–63.CrossRefGoogle Scholar
  18. 18.
    Zhang Z, Chen L, Ni H. The effectiveness of corticosteroids on mortality in patients with acute respiratory distress syndrome or acute lung injury: a secondary analysis. Sci Rep. 2015;5:17654.CrossRefGoogle Scholar
  19. 19.
    Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671–84.CrossRefGoogle Scholar
  20. 20.
    Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ. 2008;336(7651):1006–9.CrossRefGoogle Scholar
  21. 21.
    Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20(1):329.CrossRefGoogle Scholar
  22. 22.
    Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348(8):683–93.CrossRefGoogle Scholar
  23. 23.
    Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317(11):653–8.CrossRefGoogle Scholar
  24. 24.
    Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004;329(7464):480.CrossRefGoogle Scholar
  25. 25.
    Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552.CrossRefGoogle Scholar
  26. 26.
    Hashimoto S, Sanui M, Egi M, et al. The clinical practice guideline for the management of ARDS in Japan. J Intensive Care. 2017;5:50.CrossRefGoogle Scholar
  27. 27.
    Dinarello CA. Anti-inflammatory agents: present and future. Cell. 2010;140(6):935–50.CrossRefGoogle Scholar
  28. 28.
    Hilgendorff A, Muth H, Parviz B, et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2003;41(9):397–401.CrossRefGoogle Scholar
  29. 29.
    Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288(6):L1026–32.CrossRefGoogle Scholar
  30. 30.
    Kruger PS, Terblanche M. Statins in patients with sepsis and ARDS: is it over? No. Intensive Care Med. 2017;43(5):675–6.CrossRefGoogle Scholar
  31. 31.
    Alhazzani W, Truwit J. Statins in patients with sepsis and ARDS: is it over? Yes. Intensive Care Med. 2017;43(5):672–4.CrossRefGoogle Scholar
  32. 32.
    McAuley D, Charles PE, Papazian L. Statins in patients with sepsis and ARDS: is it over? We are not sure. Intensive Care Med. 2017;43(5):677–9.CrossRefGoogle Scholar
  33. 33.
    Wan YD, Sun TW, Kan QC, Guan FX, Zhang SG. Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies. Crit Care. 2014;18(2):R71.CrossRefGoogle Scholar
  34. 34.
    Pasin L, Landoni G, Castro ML, et al. The effect of statins on mortality in septic patients: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(12):e82775.CrossRefGoogle Scholar
  35. 35.
    Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014;370(23):2191–200.CrossRefGoogle Scholar
  36. 36.
    Nagendran M, McAuley DF, Kruger PS, et al. Statin therapy for acute respiratory distress syndrome: an individual patient data meta-analysis of randomised clinical trials. Intensive Care Med. 2017;43(5):663–71.CrossRefGoogle Scholar
  37. 37.
    Toner P, McAuley DF, Shyamsundar M. Aspirin as a potential treatment in sepsis or acute respiratory distress syndrome. Crit Care. 2015;19:374.CrossRefGoogle Scholar
  38. 38.
    Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest. 2009;119(11):3450–61.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Eisen DP, Reid D, McBryde ES. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med. 2012;40(6):1761–7.CrossRefGoogle Scholar
  40. 40.
    Sossdorf M, Otto GP, Boettel J, Winning J, Losche W. Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. Crit Care. 2013;17(1):402.CrossRefGoogle Scholar
  41. 41.
    Boyle AJ, di Gangi S, Hamid UI, et al. Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis. Crit Care. 2015;19:109.CrossRefGoogle Scholar
  42. 42.
    Panka BA, de Grooth HJ, Spoelstra-de Man AM, Looney MR, Tuinman PR. Prevention or treatment of ards with aspirin: a review of preclinical models and meta-analysis of clinical studies. Shock. 2017;47(1):13–21.CrossRefGoogle Scholar
  43. 43.
    O’Neal HR Jr, Koyama T, Koehler EA, et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med. 2011;39(6):1343–50.CrossRefGoogle Scholar
  44. 44.
    Kor DJ, Erlich J, Gong MN, et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med. 2011;39(11):2393–400.CrossRefGoogle Scholar
  45. 45.
    Kor DJ, Carter RE, Park PK, et al. Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A randomized clinical trial. JAMA. 2016;315(22):2406–14.CrossRefGoogle Scholar
  46. 46.
    Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997;336(13):912–8.CrossRefGoogle Scholar
  47. 47.
    Matthay MA, McAuley DF, Ware LB. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med. 2017;5(6):524–34.CrossRefGoogle Scholar
  48. 48.
    Pugia MJ, Lott JA. Pathophysiology and diagnostic value of urinary trypsin inhibitors. Clin Chem Lab Med. 2005;43(1):1–16.CrossRefGoogle Scholar
  49. 49.
    Wakahara K, Kobayashi H, Yagyu T, et al. Bikunin suppresses lipopolysaccharide-induced lethality through down-regulation of tumor necrosis factor- alpha and interleukin-1 beta in macrophages. J Infect Dis. 2005;191(6):930–8.CrossRefGoogle Scholar
  50. 50.
    Ueki M, Taie S, Chujo K, et al. Urinary trypsin inhibitor reduces inflammatory response in kidney induced by lipopolysaccharide. J Biosci Bioeng. 2007;104(4):315–20.CrossRefGoogle Scholar
  51. 51.
    Cao YZ, Tu YY, Chen X, Wang BL, Zhong YX, Liu MH. Protective effect of Ulinastatin against murine models of sepsis: inhibition of TNF-alpha and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol. 2012;64(6):543–7.CrossRefGoogle Scholar
  52. 52.
    Kawai S, Sakayori S, Watanabe H, Kobayashi H. Usefulness of a protease inhibitor (urinastatin) in ARDS with infectious diseases. Nihon Kyobu Shikkan Gakkai Zasshi. 1990;28(6):843–51.PubMedGoogle Scholar
  53. 53.
    Karnad DR, Bhadade R, Verma PK, et al. Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014;40(6):830–8.CrossRefGoogle Scholar
  54. 54.
    Yadav H, Cartin-Ceba R. Balance between hyperinflammation and immunosuppression in sepsis. Semin Respir Crit Care Med. 2016;37(1):42–50.CrossRefGoogle Scholar
  55. 55.
    Seeley EJ, Bernard GR. Therapeutic targets in sepsis: past, present, and future. Clin Chest Med. 2016;37(2):181–9.CrossRefGoogle Scholar
  56. 56.
    Patil NK, Bohannon JK, Sherwood ER. Immunotherapy: a promising approach to reverse sepsis-induced immunosuppression. Pharmacol Res. 2016;111:688–702.CrossRefGoogle Scholar
  57. 57.
    de Vriese AS, Vanholder RC, Pascual M, Lameire NH, Colardyn FA. Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med. 1999;25(9):903–10.CrossRefGoogle Scholar
  58. 58.
    Sieberth HG, Kierdorf HP. Is cytokine removal by continuous hemofiltration feasible? Kidney Int Suppl. 1999;72:S79–83.CrossRefGoogle Scholar
  59. 59.
    Yadav H, Thompson BT, Gajic O. Fifty years of research in ARDS. Is acute respiratory distress syndrome a preventable disease? Am J Respir Crit Care Med. 2017;195(6):725–36.CrossRefGoogle Scholar
  60. 60.
    Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107–16.CrossRefGoogle Scholar
  61. 61.
    Guerin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–68.CrossRefGoogle Scholar
  62. 62.
    Spragg RG, Bernard GR, Checkley W, et al. Beyond mortality: future clinical research in acute lung injury. Am J Respir Crit Care Med. 2010;181(10):1121–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Jiaxiang Zhang
    • 1
  • Ruilan Wang
    • 1
  1. 1.Department of Critical Care MedicineShanghai General Hospital, Shanghai Jiao Tong University, School of MedicineShanghaiChina

Personalised recommendations